Variable | Stage IV (< 30% predicted) (n = 937) | Stage III (30% to < 50% predicted) (n = 3019) | Stage II (≥ 50% predicted) (n = 2156) | Total population (n = 6112) |
---|---|---|---|---|
age, mean (years) | 64.2 ± 7.8 | 65.4 ± 8.1 | 64.9 ± 8.7 | 65.0 ± 8.3 |
male (%) | 83 | 76 | 72 | 76 |
BMI, mean (kg/m2) | 23.5 ± 4.9 | 25.1 ± 5.0 | 26.6 ± 5.2 | 25.4 ± 5.2 |
smoking status: current (%) | 34 | 43 | 47 | 43 |
exacerbations | ||||
number requiring antibiotics and/or oral corticosteroids, mean | 1.3 ± 1.5 | 1.0 ± 1.4 | 0.9 ± 1.2 | 1.0 ± 1.3 |
number requiring hospitalization, mean | 0.4 ± 0.7 | 0.3 ± 0.7 | 0.2 ± 0.5 | 0.2 ± 0.6 |
post-bronchodilator FEV1, mean (ml) | 704 ± 160 | 1108 ± 263 | 1616 ± 399 | 1226 ± 443 |
% predicted post-bronchodilator FEV1, mean | 24.6 ± 4.0 | 40.1 ± 5.7 | 58.8 ± 7.4 | 44.3 ± 13.4 |
SGRQ score, mean | (n = 730) | (n = 2460) | (n = 1761) | (n = 4951) |
total score | 56.5 ± 15.0 | 50.0 ± 16.5 | 45.4 ± 17.7 | 49.3 ± 17.1 |
symptoms score | 67.0 ± 18.0 | 63.5 ± 19.3 | 60.3 ± 21.0 | 62.9 ± 19.9 |
activity score | 73.4 ± 16.7 | 64.1 ± 19.0 | 57.1 ± 20.6 | 63.0 ± 20.0 |
impact score | 43.6 ± 18.6 | 37.7 ± 18.8 | 33.6 ± 19.6 | 37.1 ± 19.3 |
reversibility as % of predicted FEV1, mean | 2.5 ± 3.2 | 3.6 ± 3.6 | 4.3 ± 4.0 | 3.7 ± 3.7 |